A dopamine releasing agent (DRA) is a type of drug which induces the release of dopamine in the body and/or brain. No selective and robust DRAs are currently known. On the other hand, many releasing agents of both dopamine and norepinephrine (norepinephrine–dopamine releasing agents or NDRAs) and of serotonin, norepinephrine, and dopamine (serotonin–norepinephrine–dopamine releasing agents or SNDRAs) are known. Serotonin–dopamine releasing agents (SDRAs), for instance 5-chloro-αMT, are much more rare and are not selective for dopamine release but have also been developed. The tryptamines, like 5-chloro-αMT, are the only known releaser scaffold that consistently release dopamine more potently than norepinephrine. Examples of major NDRAs include the psychostimulants amphetamine and methamphetamine, while an example of an SNDRA is the entactogen methylenedioxymethamphetamine (MDMA). These drugs are frequently used for recreational purposes and encountered as drugs of abuse. Selective DRAs, as well as NDRAs, have medical applications in the treatment of attention deficit hyperactivity disorder (ADHD). A closely related type of drug is a dopamine reuptake inhibitor (DRI). Various selective DRIs are known, like amineptine, modafinil, and vanoxerine, in contrast to the case of DRAs. It is of particular note that the mechanism of action at the dopamine transporter (DAT) for dopamine releasers/substrates is entropy-driven (i.e. hydrophobic), whereas for dopamine re-uptake inhibitors it is enthalpy-driven (i.e. conformational change). Dextromethamphetamine is one of the most selective releasers of dopamine over norepinephrine, but it is still fairly balanced as an NDRA. Another of the most specific dopamine releasers is recreational stimulant 4-methylaminorex, but it also has considerable activity as a norepinephrine releaser and hence is likewise not a selective DRA. Pemoline, which is structurally related to the aminorex drugs, is a stimulant used to treat ADHD which acts as a selective DRI and DRA, but only weakly stimulates dopamine release. There is some albeit mixed in-vitro evidence that the antidepressant and modestly selective DRI amineptine may in addition to inhibiting the reuptake of dopamine selectively induce the presynaptic release of dopamine without affecting that of norepinephrine or serotonin. The lack of selective DRAs as of present is related to the fact that it has proven extremely difficult to separate dopamine transporter (DAT) affinity from norepinephrine transporter (NET) affinity and retain releasing capability at the same time. Selective DRAs might have different clinical effects in the treatment of attention deficit hyperactivity disorder (ADHD) than the NDRAs like amphetamines that are currently used. Although no definite selective DRAs have been described, one possible exception is 2-fluoromethcathinone (2-FMC). It has an EC50 for dopamine release of 48.7nM and induces 85% release of norepinephrine at a concentration of 10μM. For comparison, the EC50 values of methcathinone are 49.9nM for dopamine release and 22.4nM for norepinephrine release and it induces 100% release of norepinephrine at a concentration of 10μM. Hence, compared to methcathinone, 2-FMC appears to be relatively more selective or efficacious for induction of dopamine release over norepinephrine release. In any case, the EC50 of 2-FMC for induction of norepinephrine release does not seem to be available.